HealthEquity Q4 2024 Adj EPS $0.63 Beats $0.56 Estimate, Sales $262.400M Beat $258.466M Estimate
Portfolio Pulse from Benzinga Newsdesk
HealthEquity (HQY) reported Q4 2024 adjusted EPS of $0.63, surpassing the $0.56 estimate, with sales of $262.4M exceeding the $258.466M forecast. This represents a 12.21% increase in sales compared to the same period last year.
March 19, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HealthEquity reported a strong Q4 2024 performance with adjusted EPS of $0.63 and sales of $262.4M, both exceeding analyst estimates.
HealthEquity's Q4 2024 earnings and sales beat not only demonstrates the company's ability to exceed analyst expectations but also indicates a significant year-over-year growth in sales (12.21%). This positive performance is likely to instill investor confidence and could lead to a short-term uptick in HQY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100